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CXCR4 and its ligand CXCL12 mediate the homing of progenitor cells in the bone 
marrow and their recruitment to sites of injury, as well as affect processes such as cell 
arrest, survival, and angiogenesis. CXCL12 was long thought to be the sole CXCR4 
ligand, but more recently the atypical chemokine macrophage migration inhibitory fac-
tor (MIF) was identified as an alternative, non-cognate ligand for CXCR4 and shown 
to mediate chemotaxis and arrest of CXCR4-expressing T-cells. This has complicated 
the understanding of CXCR4-mediated signaling and associated biological processes. 
Compared to CXCL12/CXCR4-induced signaling, only few details are known on MIF/
CXCR4-mediated signaling and it remains unclear to which extent MIF and CXCL12 
reciprocally influence CXCR4 binding and signaling. Furthermore, the atypical chemokine 
receptor 3 (ACKR3) (previously CXCR7) has added to the complexity of CXCR4 signaling 
due to its ability to bind CXCL12 and MIF, and to evoke CXCL12- and MIF-triggered 
signaling independently of CXCR4. Also, extracellular ubiquitin (eUb) and the viral protein 
gp120 (HIV) have been reported as CXCR4 ligands, whereas viral chemokine vMIP-II 
(Herpesvirus) and human β3-defensin (HBD-3) have been identified as CXCR4 antago-
nists. This review will provide insight into the diversity and inter-connections in the CXCR4 
receptor/ligand family. We will discuss signaling pathways initiated by binding of CXCL12 
vs. MIF to CXCR4, elaborate on how ACKR3 affects CXCR4 signaling, and summarize 
biological functions of CXCR4 signaling mediated by CXCL12 or MIF. Also, we will dis-
cuss eUb and gp120 as alternative ligands for CXCR4, and describe vMIP-II and HBD-3 
as antagonists for CXCR4. Detailed insight into biological effects of CXCR4 signaling und 
underlying mechanisms, including diversity of CXCR4 ligands and inter-connections with 
other (chemokine) receptors, is clinically important, as the CXCR4 antagonist AMD3100 
has been approved as stem cell mobilizer in specific disease settings.
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BOX 1 | Chemokines and chemokine receptors.
Chemokines are 8–10 kDa small proteins that belong to the superfamily of 
cytokines and induce chemotactic cell migration by binding to their corre-
sponding receptors. In this way, chemokines mediate the formation of tissues, 
e.g., during embryogenesis or wound healing, as well as the recruitment 
of immune cells out of the bloodstream to sites of injury and infection (17). 
Chemokines are classified into four conventional subgroups according to the 
number and positioning of certain conserved N-terminal cysteine residues. 
The C-chemokines exhibit only one N-terminal cysteine, while the CC-family 
has two cysteines localized side by side. In the CXC chemokine family, the two 
cysteines are spaced from each other by one amino acid, whereas in CX3C 
chemokines they are separated by three amino acids (12, 18). Additionally, 
a family of chemokine-like function (CLF) chemokines was defined to exhibit 
typical chemokine activities in the absence of a prototypical N-terminal 
cysteine motif (19).
Chemokines mediate their effects by binding to corresponding chemokine 
receptors, whose nomenclature aligns with their ligands, i.e., CR, CCR, CXCR, 
and CX3CR. More generally, chemokine receptors are divided into two groups: 
the GPCRs, which signal via G proteins and induce various cellular functions 
including cell migration or leukocyte arrest, and the atypical chemokine recep-
tors (ACKRs), which are structurally homologous to the GPCRs but are unable 
to couple to G proteins due to a lacking cytosolic DRYLAIV motif, and fail to 
induce classical chemokine signaling. Because ACKRs efficiently internalize 
their ligands, they can function, on the one hand, as chemokine decoy recep-
tors and, on the other hand, they concentrate chemokines in hard-to-reach 
domains (20). For example, chemokine transcytosis across biological barriers 
mediated by the ACKR “DARC” on venular endothelial cells was shown to 
result in apical retention of chemokines and enhanced leukocyte migration 
across DARC-expressing monolayers (21).
Some chemokines exclusively bind to one receptor, while others bind a variety 
of receptors. Inversely, some chemokine receptors only bind one ligand, 
while others bind several chemokines (12, 18). This variability is referred to 
as “redundancy” or “promiscuity.” In addition, chemokine receptor expres-
sion varies between different cell types. This capacious complexity of the 
chemokine/chemokine receptor network enables the fine-tuned recruitment 
of defined cell types to their place of destination (18).
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introduction
The CXC chemokine receptor CXCR4 is well known for its role 
in the homing of progenitor cells into the bone marrow. Upon 
injury or stress or CXCR4 blockade, progenitor cell mobilization 
to the periphery is enhanced (1). These functions are based on 
the role of CXCR4 in mediating the chemotaxis and/or arrest 
of CXCR4-expressing progenitor cells triggered by the CXCR4 
ligand CXCL12, which is secreted by bone marrow stromal cells, 
but also increased in the periphery at sites of injury or cell stress. 
Similarly, CXCR4 influences trafficking of other cell types such 
as lymphocytes and neutrophils, but also CXCR4-positive cancer 
cells. Based on these functions, CXCR4 has been widely studied 
in different diseases. For example, blocking the CXCL12/CXCR4 
axis with the CXCR4 antagonist AMD3100 or Plerixafor is clini-
cally approved for the mobilization of hematopoietic progenitor 
cells in combination with granulocyte-colony stimulating factor 
(G-CSF) in patients with non-Hodgkin’s lymphoma and multiple 
myeloma (2). Furthermore, CXCR4 has been intensively studied 
in conditions of injury and ischemia, such as vascular restenosis 
upon stent implantation or myocardial infarction, respectively, as 
reviewed in detail recently elsewhere (1). Also, CXCR4 has been 
under intensive investigation in the area of cancer and different 
auto-immune diseases such as rheumatoid arthritis and systemic 
lupus erythematosus (2, 3). Mostly, these roles of CXCR4 have 
been linked to its capacity to bind its cognate ligand CXCL12.
However, it has become clear that CXCR4-mediated signaling 
is more complex as initially thought, as also macrophage migration 
inhibitory factor (MIF) and extracellular ubiquitin (eUb) have 
been shown to bind CXCR4 and induce intracellular signaling 
(4, 5). Furthermore, the chemokine receptor ACKR3 (previously 
CXCR7) has added to the complexity of CXCR4 signaling due 
to its ability to bind not only CXCL11 but also CXCL12 and to 
interact with MIF, regulating ligand availability for CXCR4 and 
evoking CXCL12- and MIF-triggered signaling independently 
from CXCR4 (6, 7). Also, the endogenous, antimicrobial protein 
human β3-defensin (HBD-3) was identified as a novel antagonist 
of CXCR4, blocking CXCL12-induced CXCR4 signaling (8). 
Moreover, CXCR4 binds the exogenous HIV protein gp120, 
and is therefore crucially involved in HIV infection (2, 9). On 
the other hand, CXCR4 is antagonized by the viral macrophage 
inflammatory protein-II (vMIP-II). vMIP-II is a CC chemokine 
expressed by Kaposi’s sarcoma-associated herpesvirus, func-
tions as an antagonist for multiple chemokine receptors, and is 
employed by the virus to escape the host immune system (10, 11).
Here, we will summarize the structural characteristics of the 
chemokine receptor CXCR4, its chemokine ligands CXCL12 and 
MIF, as well as non-canonical and non-host ligands eUb and HIV 
gp120. We will review and discuss current knowledge on intracel-
lular signaling through CXCR4 and biological effects triggered by 
each of these CXCR4 ligands, and will elaborate on how ACKR3 
modulates classical CXCR4 signaling triggered by CXCL12. Also, 
we will discuss the antimicrobial protein HBD-3 as well as the 
viral chemokine vMIP-II as an endogenous, respectively, viral 
antagonist for CXCR4 (8, 10), summarize the efforts that have 
been undertaken in developing CXCR4 antagonists for clinical 
use, and summarize clinical trials that are currently ongoing and 
that target CXCR4 in different pathologies. Getting insight into 
the signaling mechanisms of CXCR4 by different ligands, modu-
lation by CXCR4-containing receptor complexes and resulting 
biological effects is important to understand the potential merits 
of CXCR4 inhibition in the context of different pathologies, 
but also to be able to foresee potential side effects of long-term 
interference with CXCR4.
Structural Characteristics Affecting 
CXCR4 Functional Properties
The Chemokine Receptor CXCR4
Chemokines carry conserved cysteine motifs and are defined by 
those cysteine “signature motifs.” This has led to a categorization 
into four classes of chemokines, i.e., the CXC, CC, C, or CX3C 
chemokines where C is a cysteine residue and X any amino acid 
(aa) residue (12) (Box 1). Chemokine receptors represent a sub-
class of G protein-coupled receptors (GPCRs). Since chemokine 
receptors are classified according to the respective ligand classes, 
CXCR4 belongs to the family of CXC chemokine receptors 
(12, 13). Historically, CXCR4 was termed leukocyte-derived 
seven-transmembrane domain receptor (LESTR) following its 
cloning from a cDNA library of human monocytes in 1994 (14). 
Alternative names were cluster of differentiation 184 (CD184) 
and fusin, the latter defined as a co-factor for the fusion and entry 
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of HIV-1 (15). The term CXCR4 was proposed by Oberlin et al. 
in 1996, who were the first to describe CXCL12 as a ligand for 
this receptor (16).
CXCR4 is an evolutionary conserved protein with 89% simi-
larity between the human [352 aa] and mouse (359 aa) ortholog 
(22). Ubiquitous expression of CXCR4 has been detected in bone 
marrow, lymph nodes, liver, lung, brain, heart, kidney, thymus, 
stomach, pancreas, spleen, ovary, and small intestine (23). Similar 
to other GPCRs, CXCR4 has an extracellular N-terminus (34 aa for 
CXCR4), seven transmembrane alpha helices connected by three 
extracellular and three intracellular loops (ICL), and a C-terminus 
that is located in the cytoplasm (Figure 1A). However, analysis of 
crystal structures of CXCR4 in complex with the small-molecular 
antagonist IT1t and the cyclic peptide antagonist CVX15 in 2010 
revealed specific differences in the orientation of the alpha helices 
compared with other available GPCR structures, mostly at the 
extracellular side (24). One important difference is the extension 
of the extracellular end of helix VII, which is two helical turns 
longer as in other GPCR structures and allows a disulfide bond 
of Cys274 in helix VII with Cys28 in the N-terminal region. This 
disulfide bond, together with and among chemokine receptors 
highly conserved disulfide bond between extracellular loop 
2 (ECL2, Cys186) and the extracellular end of alpha helix III 
(Cys109), is essential for CXCL12 binding by shaping the entrance 
to the ligand-binding pocket (24). Compared to the extracellular 
half of CXCR4, which overall substantially differs from other 
GPCRs, the intracellular part of CXCR4 is structurally fairly 
similar to the intracellular half of other GPCRs. As exception, 
the intracellular part of helix VII of CXCR4 is one turn shorter 
compared to other available GPCR structures. Furthermore, the 
CXCR4 crystal structure lacks the short alpha helix VIII present 
in many GPCRs and also lacks in its C-terminus a palmitoylation 
site, which in many GPCRs attaches to the lipid membrane (24). 
Crystallization studies revealed CXCR4 to exist as a homodimer, 
however, left open the possibility of CXCL12/CXCR4 binding 
in a 1:1 or 1:2 ligand:receptor stoichiometry (24). Recently, a 
combination of computational, functional, as well as biophysical 
methods supported a 1:1 over a 1:2 CXCL12:CXCR4 binding 
stoichiometry (25). This was recently further supported by the 
crystal structure of CXCR4 in complex with the high-affinity 
antagonist vMIP-II encoded by Kaposi’s sarcoma-associated 
herpesvirus (as discussed in more detail later). CXCR4 interacted 
as a dimer with vMIP-II in a 1:1 stoichiometry (11). In addition 
to homodimerization, CXCR4 can also form dimers with ACKR3 
and other receptors, as discussed in detail later.
Upon ligand binding, CXCR4 is internalized by endocytosis 
and degraded in lysosomes, mediated by a degradation motif 
(SSLKILSKGK) in its C-terminus and ubiquitination of vicinal 
lysine residues (28).
endogenous Ligands of CXCR4: CXCL12, MiF, 
and eUb
CXCL12
The chemokine CXCL12 or stromal cell-derived factor-1 (SDF-1), 
which is the best known ligand of CXCR4, i.e., the “cognate” 
ligand of CXCR4, is highly conserved between mouse and human 
(>92%), suggesting an evolutionarily important role (29). Six 
isoforms of human CXCL12 have been defined, with CXCL12-α 
and CXCL12-β representing the major (“classical”) isoforms, 
and CXCL12-γ, CXCL12-δ, CXCL12-ε, and CXCL12-φ being 
less well characterized. CXCL12 isoforms are generated by dif-
ferential splicing events. All isoforms share the first three exons, 
FiGURe 1 | Three-dimensional structure of the chemokine receptor 
CXCR4 and its ligands CXCL12 and MiF. (A) Crystal structure of CXCR4 
[Protein data bank identifier 3ODU; (24)]. Included in the crystal structure are 
amino acids (aa) 27 to 319 of the 352 residues of CXCR4. CXCR4 can exist as 
a homodimer; here, only chain A is depicted. The N-terminal aa 27–31 are 
depicted in blue, extracellular loop 1 (aa 100–104) in red, extracellular loop 2 
(aa 174–192) in purple, and extracellular loop 3 (aa 267–273) in orange. 
Intracellular loops (ICL) 1 (aa 65–71), ICL2 (aa 140–144), and ICL3 (aa 
225–230) are depicted in cyan. The C-terminal aa 315–319 are shown in 
yellow. The degradation motif SSLKILSKGK (aa 324–333) cannot be depicted 
here due to the shortened sequence in the crystal structure. (B) Crystal 
structure of CXCL12 isoform α [Protein data bank identifier 3GV3; (26)]. 
Included in the crystal structure are aa 4–67 (with aa counting referring to the 
mature CXCL12). Here, a CXCL12 monomer is depicted with the N-terminal aa 
4–7 in blue. The RFFESH motif (aa 12–17), which is the most important binding 
motif for CXCR4 in the CXCL12 core, is depicted in red. Each monomer 
includes a three-stranded β-sheet and one α-helix. (C) Crystal structure of MIF 
[Protein data bank identifier 3DJH; (27)]. Included in the crystal structure are aa 
2–114 (with aa counting including Met-1). A MIF monomer is depicted. The 
N-terminal aa 2–5 are shown in orange. Depicted in red is the pseudo-(E)LR 
motif (Asp45–X–Arg12), the N-like loop (aa 48–57) is depicted in blue. Each 
monomer includes two antiparallel α-helices and a four-stranded β-sheet. Two 
additional, short β-strands (aa 48–50 and aa 107–109) can be found in each 
monomer stabilized by trimer formation, and are indicated with “β-strand*.”
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with observed differences in the fourth exon only. The CXCL12-α 
pro-protein (before N-terminal processing and secretion) is 
an 89 aa protein, while the other isoforms have extensions at 
the C-terminus with an additional 4 aa (CXCL12-β), 20 aa 
(CXCL12-γ), 51 aa (CXCL12-δ), 1 aa (CXCL12-ε), and 11 aa 
(CXCL12-φ) (1, 30). Not all isoforms show an identical expres-
sion pattern, with CXCL12-γ in adult mice mainly expressed 
in brain, heart, and the endothelium of vessels, compared to a 
broader expression pattern of CXCL12-α (31). On functional 
level, most research has focused on CXCL12-α, and the isoforms 
CXCL12-β and even to a higher extent -γ, -δ, -ε, and -φ have 
still been poorly characterized. However, functional differences 
have been revealed between the different isoforms, with, for 
example, CXCL12-γ binding the receptor CXCR4 with only low 
affinity and triggering reduced chemotaxis in  vitro compared 
to CXCL12-α (31, 32). Also, the γ isoform has been shown to 
be present in the nucleus of mouse cardiac tissue by transcrip-
tion of a distinct mRNA lacking the N-terminal signal peptide 
responsible for chemokine secretion (as explained in more detail 
below), suggesting specific intracellular functions different 
from the extracellular functions of the α and β isoforms (33). 
Furthermore, an isoform-specific role of CXCL12 has previously 
been suggested in the context of cerebral ischemia, where leuko-
cyte infiltration was associated with endothelial CXCL12-β but 
not −α (34). In comparison to the human system, there are only 
three CXCL12 isoforms described in mouse. These are Cxcl12-α, 
-β, and -γ, which correspond to the respective human isoform 
counterparts, with only a single homologous aa substitution (Val 
to Ile substitution at aa 18 in the mature CXCL12 protein) from 
human to mouse (32, 33, 35).
The CXCL12 “pro-protein” contains a signal peptide of 21 aa at 
the CXCL12 N-terminus, which is cleaved off before secretion of 
the mature, biologically active CXCL12 protein. In the literature, 
residue numbers of important motifs of CXCL12 are numbered 
starting from Lys-22 in the pro-protein, now being counted 
as Lys-1 in the mature protein. The CXCL12 residue numbers 
mentioned in this manuscript are numbered accordingly.
The structure of the mature CXCL12 protein is characterized 
by a three-stranded β-sheet that is packed against an α-helix 
(Figure  1B) and extends to a six-stranded β-sheet in dimeric 
CXCL12 species (see below). The N-terminus of mature CXCL12, 
in particular the first two residues Lys-1 and Pro-2 (with aa indi-
cation referring to their position in mature CXCL12 throughout 
this manuscript), is essential for CXCR4 activation, as shown by 
the observation that loss of these first two residues completely 
abolished CXCR4 activation, while CXCR4 binding affinity 
was decreased 10-fold (36). A report by Crump et al. (36) and 
subsequent studies (18) support a so-called “two-site” model 
of chemokine binding to their receptors: “Site one” consists of 
the chemokine core domain and is responsible for docking of 
the chemokine to its receptor. In CXCL12, the most important 
core domain for CXCR4 binding is the so-called RFFESH motif 
(residues 12–17 in mature CXCL12). “Site two” consists of the 
N-terminus of CXCL12, more precisely especially Lys-1 and 
Pro-2, which activate CXCR4 signaling (36). The differential 
C-termini in the different CXCL12 isoforms are not involved in 
either of these site one or two interactions with CXCR4.
This “two-site” model has been proposed as a general 
functional mechanism of chemokines for a long time (18, 37). 
However, which residues of CXCR4 in particular are involved in 
site one and site two interaction with CXCL12 still remains to be 
elucidated in more detail. An important contribution to CXCL12 
binding was revealed to occur through posttranslational sulfation 
of tyrosine residues in the CXCR4 N-terminus (Tyr-21, Tyr-12, 
Tyr-7). This increases the binding affinity of CXCR4 for CXCL12 
through electrostatic interactions between acidic sulfated tyros-
ines within CXCR4 and basic residues within CXCL12 (38, 39) 
and is expected to contribute to “site one” interaction between 
CXCR4 and CXCL12. More specifically, sulfated Tyr-21 was 
recently predicted to interact with the N-loop-β1 strand junction 
within CXCL12 based on the crystal structure of CXCR4 bound to 
the viral chemokine vMIP-II (11). Furthermore, this latter study 
revealed within the β3 strand of vMIP-II a stretch of four residues 
(RQVC, aa 48–51) that interacted with CXCR4 residues D22 and 
E26 and that was previously shown to be important for interac-
tion of CXCR4 with vMIP-II (11). These same residues RQVC 
are conserved in CXCL12 (aa 47–50), also previously shown to 
be important for CXCL12/CXCR4 binding, and structural mod-
eling predicted their involvement in CXCL12/CXCR4 interaction 
comparably to vMIP-II/CXCR4 interaction (11). Furthermore, 
the crystal structure of CXCR4 in complex with IT1t as competi-
tive antagonist of CXCL12 revealed as important ligand/receptor 
contact points the acidic residues Asp-187, Glu-288, and Asp-97 
in CXCR4, which were previously also shown to be important for 
CXCL12 binding (24). With respect to the “site two” interaction 
important for receptor signaling, the crystal structure of CXCR4 
in complex with the antagonistic peptide CVX15 was suggested 
to reveal a “site two” interaction of the CXCL12 N-terminus 
(aa 1–8 KPVSLSYR) with CXCR4, with preliminary modeling 
studies suggesting that CXCL12 Lys-1 could integrate into the 
CXCR4 binding pocket and interact with available acidic aa (24). 
Together, these findings underline the notion that important 
insights into the interaction of CXCR4 with its ligand CXCL12 
can be deduced from available crystal structures of CXCR4 with 
other ligands or small-molecule antagonists.
Mature CXCL12 is intrinsically unstable and truncated vari-
ants of mature CXCL12 missing 2,3,5 or 7 N-terminal aa have been 
identified in human blood, with only non-truncated CXCL12 
able to induce intracellular calcium flux and chemotaxis of stem 
cells in vitro (40). Proteases able to inactivate CXCL12 by cleaving 
off N-terminal residues from CXCL12 in vitro include dipeptidyl 
peptidase 4 (DPP4, also known as CD26), matrix metalloprotein-
ase 2, neutrophil elastase, and cathepsin G (Box 2). For example, 
CXCL12 has a half-life of less than 1 min for truncation by DPP4 
in vitro (41). This intrinsic instability of CXCL12 could at least 
partly contribute to the short life-time of CXCL12 in vivo, with 
wild-type CXCL12 effectively cleared from mouse blood within 
1 h of intravenous application (42).
In addition, fast clearance of CXCL12 from blood seems to 
be partially mediated by sequestration of CXCL12 to heparan 
sulfate on the surface of endothelial cells through the BBXB 
heparin sulfate-binding motif (aa) KHLK in position 24–27; with 
B = basic aa and X = any other aa) in the first strand of the β-sheet 
of CXCL12 (50): a CXCL12 mutant that failed to bind heparan 
BOX 2 | instability of CXCL12.
Signaling of the CXCL12/CXCR4 axis is tightly regulated. One way how 
signaling can be terminated is by proteolytic cleavage of CXCL12. Particularly 
interesting is dipeptidyl peptidase IV (DPP4, also known as CD26), an enzyme 
that cleaves off the first two residues of CXCL12 (43), as also shown in human 
serum (44). Removal of these first two amino acids is sufficient to completely 
abolish CXCL12-induced CXCR4 activation despite an only 10-fold reduction 
in CXCR4 binding (36). DPP4, which can be membrane-expressed in addition 
to its soluble form, also co-localizes and co-immunoprecipitates with CXCR4 
(45), which further establishes a specific role for this protease in the regulation 
of CXCR4 signaling.
Furthermore, matrix metalloproteinase 2 (MMP-2) is capable of cleaving the 
first four N-terminal amino acids of CXCL12, and was shown to impair CXCR4 
signaling in the context of recruitment of neural progenitor cells (46). MMP-2 
was first shown to inactivate CXCL12 in in vitro experiments by McQuibban 
et al., alongside the MMP family members MMP 1, 3, 9, 13, and 14 (47). Also, 
neutrophil elastase, released from mononucleated blood cells or polymorpho-
nuclear neutrophils, can cleave the first three N-terminal residues of CXCL12 
inducing its inactivation. In addition, it can cleave the N-terminus of CXCR4, 
which significantly reduces CXCR4 binding to CXCL12 (48). Finally, cathepsin 
G has been shown to inactivate CXCL12 by cleaving the first five residues at 
the N-terminus (49).
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sulfate proteoglycans was retained up to 60% in the blood of mice 
6 h after injection (42). Of note, the C-terminus of the CXCL12-γ 
isoform encompasses an additional four overlapping BBXB 
heparan sulfate-binding motifs, which mediate strong absorption 
of CXCL12-γ on the plasma membrane after secretion through 
interaction with cell membrane glycosaminoglycans. This enables 
for efficient formation of chemokine gradients (“haptotactic 
gradients”) directing cell migration and angiogenesis in  vivo 
with higher efficiency compared to CXCL12-α, despite a lower 
binding affinity to CXCR4 (31). Although also the CXCL12-β 
isoform contains one additional BBXB motif in its C-terminus, 
it does not show higher affinity to heparin sulfate compared to 
the α-isoform. Interestingly, a knock-in mouse line carrying 
a mutated Cxcl12 that cannot bind heparin sulfate without 
effect on Cxcr4 signaling by the α, β, or γ isoform showed an 
increased number of circulating hematopoietic progenitor cells, 
but a reduction in the number of cells infiltrating ischemic tissue 
after acute hindlimb ischemia and associated revascularization 
(51). On the other hand, a recent report revealed truncation 
of five or seven N-terminal residues from CXCL12 to increase 
its binding affinity to the glycosaminoglycan heparin. As both 
truncated variants were able to induce stem cell mobilization in 
mice although they displayed in vitro no or a negative effect on 
CXCL12-induced chemotaxis, respectively, these findings may 
suggest that N-terminally truncated CXCL12 variants may influ-
ence stem cell mobilization by regulating binding of CXCL12 to 
glycosaminoglycans rather than to CXCR4 (40). Together, these 
findings reveal an important role for glycosaminoglycans in 
regulating CXCL12 functions.
Finally, in vitro experiments indicated that CXCL12 may exist 
in both monomeric and dimeric forms in the extracellular space. 
Although recent findings support a 1:1 over a 1:2 ligand:receptor 
stoichiometry for interaction of CXCR4 with both CXCL12 
(25) as well as vMIP-II (11), it remains unclear whether dimeric 
CXCR4, as revealed in crystal structures, would preferentially 
bind dimeric CXCL12 or rather two monomeric CXCL12 
proteins (24). Of note, distinct CXCL12 oligomers have been 
associated with differential downstream signaling, although with 
contradictory findings, as discussed in more detail later.
Migration inhibitory factor
Migration inhibitory factor is a 12.3  kDa small cytokine with 
chemokine-like properties. It is quasi-ubiquitously expressed in 
various tissues in mammals and its structure is highly conserved 
with about 90% sequence homology between mouse and human 
species (52). MIF consists of 115 aa, but the N-terminal methio-
nine residue is posttranslationally removed after ribosomal 
synthesis in essentially all cells and organisms. Crystallographic 
studies revealed MIF as a homotrimer consisting of three mono-
mers that each has two antiparallel α-helices and a four-stranded 
β-sheet. Two additional, short β-strands can be detected in each 
monomer which interact with the β-sheet of the adjacent subunits 
(53) (Figure 1C). However, different studies revealed MIF to be 
able to exist as monomer, dimer, trimer, or even higher-order 
oligomers, potentially concentration-dependent, although the 
biologically relevant “active” oligomerization state of MIF is still 
elusive (53–55). As interference with MIF trimerization using the 
inhibitor ebselen increased MIF’s chemotactic capacity, it is how-
ever likely that the MIF homotrimer is not the only biologically 
active form (56). For example, MIF was recently identified as a 
chaperone molecule inhibiting the accumulation and mitochon-
drial association of misfolded superoxide dismutase SOD1, and 
gel filtration fractions of cellular lysates containing this inhibitory 
potential contained monomeric as well as oligomerized MIF (57). 
Of note, a chaperone function of MIF was recently suggested 
toward insulin to ensure full insulin function through effects on 
insulin conformation (58).
Migration inhibitory factor lacks a typical N-terminal 
leader sequence indicating that it is secreted by a non-classical 
secretion pathway (59). Because MIF is missing an N-terminal 
cysteine motif, it cannot be grouped into one of the four clas-
sical chemokine groups (C, CC, CXC, and CX3C), which are 
classified by the presence and spacing of their N-terminal 
cysteine residues (Box  1). Nevertheless, MIF exhibits potent 
chemotactic properties through interaction with classical 
chemokine receptors and thus is a protagonistic member of the 
group of CLF chemokines (19, 60). MIF mediates its chemot-
actic effects by binding to the chemokine receptors CXCR2 and 
CXCR4 (4), as discussed in more detail below. MIF exhibits a 
structural motif (Asp45–X–Arg12, “DXR,” with aa numbering 
for MIF including Met-1 throughout this manuscript) similar 
to the conserved N-terminal ELR (Glu–Leu–Arg) motif of the 
cognate CXCR2 ligands, which is important for their efficient 
binding to CXCR2. In MIF’s so-called “pseudo-(E)LR motif,” 
the glutamate (Glu) is exchanged by an aspartic acid (Asp), 
representing a conservative substitution. Furthermore, the Asp 
and Arg residues in this motif are located in neighboring loops 
in 3D space, but show similar spacing as the authentic ELR 
motif (61). Mutations of Asp45 or Arg12 indeed abrogated 
MIF/CXCR2-mediated effects indicating the “pseudo-(E)
LR motif ” as structural determinant for MIF binding to 
CXCR2 (61). Additionally, an N-like loop including the aa 
from position 48 to 57 of the MIF protein was identified as 
being important for MIF-CXCR2 binding (62). These findings 
BOX 3 | Gp120.
Gp120 is the envelope protein of the HI-virus, which is responsible for the 
entry of the virus into cells (79). Hence, it is a main virulence factor of HIV. The 
position of gp120 outside the virus membrane, bound to another envelope 
protein gp41, enables binding to the CD4 receptor of the target cell (77). 
After subsequent structural rearrangement of gp120, it can bind to one of the 
HIV co-receptors, CXCR4 or CCR5, via chemokine mimicry (83). This is the 
crucial step leading to membrane fusion and consolidation of the virus with 
its target cell, thereby enabling infection (79). Furthermore, gp120 induces 
cellular apoptosis, partly through CXCR4. Molecular mechanisms underlying 
gp120/CXCR4-mediated apoptosis are discussed in more detail elsewhere 
in this review.
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suggest a two-site binding mechanism for MIF-CXCR2 interac-
tion that is reminiscent of that of cognate CXCR2 ligands. Site 
one, consisting of the N-like loop and the CXCR2 N-domain, 
supposedly initializes the interaction, while the site two inter-
action between the pseudo-(E)LR motif and the extracellular 
loops of CXCR2 is assumed to lead to receptor activation (63). 
The interaction sites between MIF and CXCR4 still need to be 
identified. Additional structural characteristics of MIF related 
to its intrinsic catalytic oxidoreductase and tautomerase activi-
ties were recently discussed at length (19, 64) and will not be 
further reflected herein.
Extracellular Ubiquitin (eUb)
Ubiquitin is a small 8.6 kDa protein constitutively expressed in 
all eukaryotic cells which displays a very conserved structure 
with only little variance from insects to humans (65). Its tightly 
controlled expression is encoded by four genes in mammals 
(66). Because its amino acid structure includes seven lysines, 
ubiquitin can build poly-chains (67). Therefore, intracellular 
ubiquitin can appear as a free monomer, a free polyubiquitin 
chain, or as a monomer or a polyubiquitin chain conjugated 
to a substrate (66). Ubiquitin is well characterized as a post-
translational protein modifier, with Lys-48-linked polyubiquitin 
chains binding covalently to lysine residues of target proteins to 
induce their degradation through the 26S ubiquitin-proteasome 
degradation pathway. However, ubiquitin also serves different 
degradation-independent functions affecting intracellular pro-
cesses in a reversible way, as, for example, in regulating protein 
activity, subcellular localization, and interaction with other 
proteins. This is mediated by a structurally different ubiquitina-
tion of target proteins, involving the coupling of target proteins 
to ubiquitin monomers or polyubiquitin chains interlinked 
through ubiquitin lysines other than Lys-48 (e.g., Lys-63) 
[reviewed in Ref. (65)].
But ubiquitin is not only an intracellular protein modifier, 
but it is also a natural plasma protein and can be detected in 
urine (68). Nevertheless, not much attention has been paid to 
ubiquitin’s “extracellular” actions. Although the existence of a cell 
surface receptor for ubiquitin was assumed since its discovery 
in 1975 (69), first evidence that CXCR4 may function as a cell 
surface receptor for ubiquitin was only revealed in 2010 upon 
studying the effect of CXCR4 antagonism or knockdown on bind-
ing of ubiquitin to CXCR4-positive cells (70). Studies concerning 
the structural determinants of the ubiquitin–CXCR4 interaction 
revealed by binding assays using fluorescently labeled ubiquitin 
indicated a two-site binding mechanism involving the flexible 
C-terminus of ubiquitin and its hydrophobic surface surround-
ing Phe-4 and Val-70. Within CXCR4, residues Phe-29, Phe-189, 
and Lys-271, which do not contribute to the CXCL12–CXCR4 
interaction interface, seem to be important for ubiquitin-CXCR4 
binding (71).
Gp120 as exogenous Ligand of CXCR4
The HI-virus (HIV) is surrounded by an envelope consisting of 
a host cell-derived lipid bilayer and virus-encoded glycoproteins. 
To enter a new target cell, the virus membrane has to be fused 
with the target cell membrane, a process mediated by the virus 
glycoprotein gp120 (Box 3) (72). Gp120 has a molecular weight 
of 120 kDa. Its secondary structure involves four surface-exposed 
loops which are formed by variable regions (V1–V4) with 
disulfide bonds at their bases. They are divided by five relatively 
conserved domains (C1–C5) (73). The envelope glycoproteins 
of HIV are encoded by the virus RNA env-gene (74). They are 
synthesized as precursors in the endoplasmic reticulum of the 
infected cell. After addition of asparagine-linked high-mannose 
sugar chains, the resulting glycoprotein gp160 is transported to 
the Golgi apparatus, where it is cleaved by cellular proteases into 
the functional envelope proteins gp120 and gp41 (75, 76). The 
mature glycoproteins gp41 and gp120 build up complexes which 
are translocated to the cell surface, where they are integrated 
into sprouting virions (77). Gp41 functions as a transmembrane 
protein and gp120 is the exterior envelope protein capping gp41 
(78). The evolving so-called Env protein, a trimer of gp41–gp120 
heterodimers, mediates target cell receptor binding (79). First, 
the CD4 binding site of gp120, consisting of the hydrophobic 
regions around Thr-257 and Trp-427 and the hydrophilic regions 
around Asp-368 and Glu-370, binds to CD4 (80). This binding 
induces rearrangement of V1 and V2 and subsequent of V3 
(81), enabling binding of V3 to the co-receptor CXCR4 or CCR5 
depending on the sequence of V3 (82). Gp120 binding to the 
chemokine receptors CXCR4 or CCR5 is thereby supposed to 
be the trigger for membrane fusion of the virus and the target 
cell, which is responsible for HIV infection (79). The mechanism 
of binding to chemokine receptors without exhibiting typical 
chemokine structures, like gp120 binding to CXCR4 or CCR5, 
is called chemokine mimicry. It is used by several viruses like 
pox or herpes viruses to strengthen their propagation by block-
ing chemokine action or triggering chemokine receptor signaling 
(83). Molecular mechanisms underlying gp120/CXCR4-induced 
cell death are discussed in more detail below.
vMiP-ii and Human β3-Defensin as Potent 
CXCR4 Antagonists
vMIP-II as Viral CXCR4 Antagonist
Chemokine mimicry, as described for gp120, is also involved 
in the interaction of CXCR4 with vMIP-II. vMIP-II is a 
chemokine-like protein encoded by the Kaposi’s sarcoma-asso-
ciated herpesvirus 8, with about 40% similarity to mammalian 
chemokines (10). It was described as a potent antagonist for 
several CC and CXC chemokines and their receptors, including 
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CXCR4, for which it competes with CXCL12 for receptor 
binding. However, in contrast to CXCL12, vMIP-II cannot 
induce Ca2+ mobilization from intracellular stores, nor induce 
chemotaxis of human monocytes (10). Zhou et al. revealed in 
2000 that the N-terminus of vMIP-II, particularly the first five 
residues, is essential for binding to CXCR4 (84). Interestingly, 
native vMIP-II was able to inhibit HIV-1 viral entry into a 
CD4-expressing U87 cell line in vitro by antagonizing CCR3, 
CCR5 as well as CXCR4 (10). A peptide corresponding to 
residues 1−21 of vMIP-II showed inhibition of HIV-1 gp120-
mediated cell−cell fusion only via CXCR4 (84). Together, these 
findings implicated vMIP-II as a promising lead molecule for 
anti-HIV drug development. vMIP-II-derived peptides are also 
being investigated as CXCR4 inhibitors in the context of cancer 
therapy (85).
HBD-3 as Endogenous CXCR4 Antagonist
Human β3-defensin was proposed as a novel, endogenous 
antagonist of CXCR4 in 2006 by Feng et al. (8). The β-defensins 
are a group of antimicrobial peptides present on mucosal epi-
thelium, which are also upregulated in the presence of HIV-1 
and block HIV replication by direct binding of virions and 
blocking of the HIV co-receptor CXCR4 (8). HBD-3 competes 
with CXCL12 for CXCR4 binding, as shown by the inhibition 
of CXCL12-induced T-cell chemotaxis, ERK1/2 activation, 
and Ca2+ mobilization upon HBD-3 treatment (8). Confocal 
microscopy showed that HBD-3 treatment induced internali-
zation of CXCR4 in a T-cell line, however HBD-3 did not trig-
ger downstream signaling such as Ca2+ mobilization or ERK 
phosphorylation, nor chemotaxis (8). The structural features 
of HBD-3 important in CXCR4 antagonism were unraveled 
by the same group in 2013, partly by structural comparison 
with CXCL12. HBD-3 is a protein of 45 aa, with six conserved 
cysteine residues (Cys-11, 18, 23, 31, 40, and 41) forming 
three disulfide bonds, which stabilize the protein (86, 87). 
Substituting these cysteine residues with uncharged aa, gener-
ating a “linearized” HBD-3, completely abrogated the inhibi-
tory effect of HBD-3 on CXCL12-triggered Ca2+mobilization 
(87). Similar effects were observed upon substituting the 
cationic residues Lys8, Lys32, and Arg36, resembling the resi-
dues Lys-1, Arg8, and Lys-12 in CXCL12, with neutral ones; 
substituting the positively charged C-terminus with negatively 
charged residues; as well as removing the first 10 N-terminal 
residues (87). Of note, such structural insights into the CXCR4 
antagonism by HBD-3 could stimulate the development of 
novel CXCR4 antagonists.
Biological Processes and Signaling 
Triggered by CXCL12 Through CXCR4
The CXCL12/CXCR4 axis is involved in a plethora of 
biological processes, including, for example, progenitor 
cell homing and mobilization, neutrophil homeostasis, 
embryonic development, and angiogenesis. These biologi-
cal effects are mediated by complex signaling mechanisms, 
including classical GPCR signaling, β-arrestin recruitment, 
or the activation of the JAK/signal transducer and activator 
of transcription (STAT) pathway. Also, oligomerization of 
CXCR4 or CXCL12, as well as interaction of CXCR4 with 
other signaling molecules affects the outcome of CXCL12/
CXCR4 signaling. Each of these aspects will be discussed in 
the following section.
Biological Processes Regulated by the  
CXCL12/CXCR4 Axis
The CXCL12/CXCR4 axis plays an important role in the hom-
ing of hematopoietic stem and progenitor cells (HSPCs) in 
the bone marrow, and their mobilization to the periphery in 
conditions of stress or injury. Homing of HSPCs is mediated 
by CXCL12 secretion by endothelial cells in the bone marrow 
sinusoids as well as by bone marrow stromal cells. CXCR4-
positive HSPCs flowing through the bloodstream are triggered 
to firmly adhere to the endothelium of bone marrow sinusoids 
through CXCL12/CXCR4-induced integrin activation (88), 
followed by their migration into specialized bone marrow 
niches. Constant trafficking of a small number of HSPCs from 
the bone marrow to the periphery occurs in normal physi-
ological state, however in certain conditions such as injury or 
stress, an increased release of HSPCs into the bloodstream can 
be observed. Since in turn CXCL12/CXCR4 signaling is essen-
tial for bone marrow retention of HSPCs, interference with 
this pathway was shown to trigger HSPC mobilization (89). 
There are several proposed mechanisms of CXCR4 interfer-
ence in the context of HSPC mobilization, as discussed in more 
detail recently (1). For example, the commonly used stem cell 
mobilizing reagent G-CSF was shown to induce the cleavage 
of the CXCR4 N-terminus on HSPCs, leading to diminished 
chemotaxis and arrest, and reduced retention of HSPCs in 
the bone marrow (90). In  vitro, such CXCR4 cleavage could 
be induced by the neutrophil proteases neutrophil elastin 
and cathepsin G (90), although the in vivo relevance requires 
further validation.
In addition to HSPC homeostasis, the CXCL12/CXCR4 axis 
has been implicated to be involved in progenitor cell survival 
and proliferation (91, 92). Also, similar to its effect on HSPCs, 
CXCL12/CXCR4 signaling regulates the homeostasis of CXCR4-
positive neutrophils and mediates their homing in the bone 
marrow through the constitutive expression of CXCL12 by bone 
marrow stromal cells (93). The retention of neutrophils in the 
bone marrow by CXCL12/CXCR4 can be blocked by the CXCR4 
antagonist AMD3100 (Plerixafor), which has been used to cor-
rect neutropenia in patients (94).
Since CXCR4 is crucial in stem cell homeostasis, it is not 
surprising that it has essential functions in embryonic develop-
ment. In fact, knockout of Cxcr4 in mice causes several lethal 
birth defects, such as defective trafficking of HSPCs from the fetal 
liver to the embryonic bone marrow, impaired B-lymphopoiesis, 
impaired vascularization, and abnormal cerebellum develop-
ment (95, 96). In addition to its role in vascularization during 
development, the CXCL12/CXCR4 also plays an important 
role in angiogenesis in the context of ischemia, as discussed 
in more detail recently (1). CXCL12 expression was shown to 
FiGURe 2 | CXCL12-induced signaling pathways. CXCL12 can trigger 
intracellular signaling by binding to CXCR4 monomers, CXCR4 homodimers, 
ACKR3, or CXCR4/ACKR3 heterodimers. CXCR4 preferentially activates G 
protein-mediated signaling, which is negatively regulated by RGS16. The 
atypical chemokine receptor ACKR3 (previously called CXCR7) functions as 
a CXCL12 scavenger and also signals via β-arrestin. Also, complex 
formation between CXCR4 and ACKR3 shifts CXCL12-induced signaling 
away from classical G protein signaling to β-arrestin signaling. By CXCL12-
induced dimerization, CXCR4 has also been reported to induce JAK/STAT 
signaling. Whereas CXCR4 is mostly degraded after CXCL12-elicited 
internalization, ACKR3 is continuously internalized and recycled to plasma 
membrane independent of ligand binding, a process that also promotes 
CXCL12 degradation. CXCL12 is known to induce chemotaxis and 
proliferation, supporting several downstream biological processes such as 
hematopoietic development, angiogenesis, or tumor progression. AKT, 
protein kinase B; Ca2+, calcium ions; Gα, G protein subunit α; Gβγ, G protein 
subunit βγ; JAK, janus kinase; MAPK, mitogen-activated protein kinase; 
PI3K, phosphatidylinositide 3-kinase; PLC, phospholipase C; RGS16, 
regulator of G protein signaling 16; STAT, signal transducer and activator of 
transcription.
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be upregulated in conditions of hypoxia in a HIF-1-dependent 
way, resulting in increased chemotaxis and adhesion of CXCR4-
positive progenitor cells to ischemic tissue (97). In a mouse 
model of myocardial ischemia, CXCL12 treatment leads to 
increased levels of vascular endothelial growth factor (VEGF) and 
enhanced neo-angiogenesis, associated with reduced infarction 
size after myocardial infarction (98). Also, the transplantation 
of CXCL12-overexpressing endothelial progenitor cells during 
myocardial infarction in rats could increase neo-angiogenesis 
(99). In ischemic preconditioning, which exerts cardioprotec-
tive effects, the levels of Cxcr4 mRNA were increased in cardiac 
myocytes and fibroblasts, suggesting also a local protective effect 
of the CXCL12/CXCR4 axis. Indeed, the in vivo administration of 
CXCL12 leads to a decrease in myocardial infarct size associated 
with signaling through the anti-apoptotic kinases ERK 1/2 and 
AKT in cardiac cells (99).
Related to its role in angiogenesis, chemotaxis (100, 101), and 
cell proliferation (100, 102), CXCL12/CXCR4 signaling has also 
been linked to different pathologies including tumor progression 
and metastasis, as discussed in more detail later.
CXCL12/CXCR4 Binding Triggers  
G Protein-Coupled Signaling
CXCR4 is classified as a GPCR, indicating that one of the main 
pathways triggered by CXCR4 stimulation involves G protein-
coupled signaling (Figure 2). The G protein complex is a hetero-
trimeric complex, composed of a Gα, Gβ, and Gγ subunit (Box 4), 
and is associated with CXCR4 and the inner leaflet of the plasma 
membrane. CXCR4 is mainly coupled to the Gαi subunit, which 
after dissociation of the Gαβγ complex upon CXCR4 stimulation, 
inhibits adenylyl cyclase activity, and triggers mitogen-activated 
protein kinases (MAPK) and phosphatidylinositol-3-kinase 
(PI3K) pathway activation (96). The Gβγ subunit leads to the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
diacylglycerol (DAG) and inositol triphosphate (IP3) by phospho-
lipase C (PLC) and subsequent mobilization of Ca2+ ions from 
intracellular stores (103, 104). This could also be considered a 
downstream effect of Gαi activity, since the inhibition of Gαi 
activity by its potent inhibitor pertussis toxin has been reported 
to lead to decreased Ca2+ mobilization from intracellular stores 
(103, 105). Although CXCR4 is most likely primarily coupled to 
BOX 4 | G protein-coupled (GPCR) signaling.
G protein-coupled signaling is a major signaling pathway in most cell types. 
The heterotrimeric G protein complex can interact with so-called GPCRs and 
is composed of the three subunits Gα, Gβ, and Gγ. In its non-active form, 
nucleotide guanosine diphosphate (GDP) is bound to the G protein complex. 
Upon ligand binding and subsequent activation and conformational change 
of the GPCR (107), GDP is replaced by guanosine triphosphate (GTP) and 
the three G protein subunits dissociate into a GTP-bound Gα monomer and 
a Gβγ dimer (108), each triggering distinct intracellular signaling pathways. 
After G protein activation, GTP is again hydrolyzed to GDP through an intrinsic 
GTPase activity of the Gα subunit, which in turn leads to re-association of the 
Gαβγ-trimer/GPCR complex and hence termination of GPCR signaling (96, 
109). The G protein subunits can be divided into several classes, with more 
than 16 different Gα isoforms, 5 Gβ isoforms, and 14 Gγ isoforms [reviewed 
in Ref. (110)]. The Gβγ subunit leads to the hydrolysis of phosphatidylinositol 
4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol triphosphate (IP3) 
by phospholipase C (PLC) and subsequent mobilization of Ca2+ ions from 
intracellular stores (103, 104). The Gα proteins are the main signal transdu-
cers, and association of GPCRs with different Gα isoforms leads to activation 
of different downstream signaling mediators. For example, Gαs induces cyclic 
AMP (cAMP) production, activating protein kinase A (PKA) and thus the tran-
scription factor cAMP-responsive element-binding protein (CREB). Both Gαi 
and Gαq are involved in activating PLC and subsequent mobilization of Ca2+ 
ions from intracellular stores, as well as inhibiting adenylyl cyclase activity and 
triggering activation of MAP kinases, the phosphatidylinositol-3-kinase (PI3K) 
pathway, and the NF-κB pathway (106).
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Gαi, recent reports suggest that CXCR4 associates with other Gα 
subunits, i.e., Gαq or Gα12, each of which has been associated with 
different intracellular signaling cascades (Box 4) (106).
RGS16 as a Negative Regulator of  
CXCL12/CXCR4 Signaling
G protein-coupled signaling triggers diverse downstream signal-
ing pathways and hence needs to be tightly regulated. Signaling 
termination is initiated by hydrolysis of Gα-bound GTP to GDP 
by an intrinsic GTPase activity of the Gα subunit, with subsequent 
re-association of the inactive G protein trimer/receptor complex 
(96, 109). This GTPase activity can be further enhanced by so-
called regulators of G protein signaling (RGS), which bind to the 
activated Gα subunit following GPCR stimulation. The family 
of RGS proteins consists of at least 37 members that all share a 
conserved 120 aa GTPase-accelerating domain (111), termed the 
RGS box (109). The family member RGS16 was identified as a 
negative regulator of CXCL12–CXCR4 signaling in 2005 (112). 
Overexpression of RGS16 leads to reduced CXCL12-induced 
migration of megakaryocytes and reduced activation of MAPK 
and the kinase AKT, whereas knockdown of RGS16 increased 
CXCR4 signaling (112). Furthermore, down-regulation of RGS16 
expression by microRNA126 in endothelial cells was shown to 
increase CXCR4 signaling, leading to an auto-regulatory positive 
feedback loop through increased production of CXCL12 (113).
involvement of the JAK/STAT Pathway in 
CXCL12/CXCR4 Signaling
Upon binding of CXCL12, CXCR4 can dimerize and becomes 
phosphorylated at intracellular tyrosine residues by rapid recruit-
ment and activation of the Janus kinases JAK2 and JAK3. These 
phosphorylated tyrosines mediate the binding of STAT proteins, 
which are phosphorylated by the CXCR4-bound JAK kinases, 
leading to STAT dimerization and initiation of the STAT signal-
ing pathway (114) (Figure  2). The phosphorylation of CXCR4 
by JAK2/3, and hence activation of the JAK/STAT pathway, is 
unaffected by treatment with the Gαi-specific inhibitor pertussis 
toxin. However, it is interesting to note that the complex of CXCR4 
with JAK2/3 does not dissociate in pertussis toxin-treated cells, 
as it would normally do. This implies that the Gαi protein could 
be involved in the recycling of the JAK/STAT receptor complex 
by uncoupling of JAK2/3 from CXCR4 (114). The precise mecha-
nism for this effect however remains unidentified.
The activation of the JAK/STAT pathway leads to diverse cellu-
lar effects, including Ca2+ mobilization from intracellular stores, 
which shows again the complex interplay with G protein-coupled 
signaling. In fact, employing a JAK-specific inhibitor, it could be 
shown that the association of Gαi to CXCR4 is dependent on JAK, 
further supporting a co-dependent mechanism of action between 
members of the JAK/STAT pathway and G protein-coupled 
signaling (115). Although activation of the JAK/STAT pathway 
by CXCR4 has interesting implications for future research, only 
limited data on this interaction are available to date.
Beta-Arrestin Modulates CXCL12/CXCR4 
Signaling
Apart from classical signaling through G protein activation, 
CXCR4 has also been shown to induce β-arrestin-mediated sign-
aling (Figure 2). β-Arrestin exists in two isoforms, β-arrestin-1 
and β-arrestin-2, which have historically been described as termi-
nators of G protein-coupled signaling. Signaling is terminated by 
recruitment of β-arrestin to the receptor site, whereby G protein 
coupling to the receptor is sterically hindered (116). In addition, 
β-arrestins facilitate the internalization of the receptor by acting as 
an adaptor for β(2)-adaptin and clathrin, transporting the recep-
tor to clathrin-coated pits for endocytosis (117). Interestingly, 
high levels of intracellular CXCR4, located in early and recycling 
endosomes, can be found constitutively in HSPCs, independent 
of ligand binding. This suggests that constitutive endocytosis of 
CXCR4 and possibly CXCR4 recycling to the cell membrane, 
mediated by clathrin-coated vesicles, are important mechanisms 
in HSPC regulation and trafficking (118). Similar findings were 
reported in fetal mesenchymal stem/stromal cells (119).
However, β-arrestin is not only involved in G protein-coupled 
signaling termination and GPCR internalization, but also initi-
ates signaling itself. One of the first findings pointing to signaling 
mediated by β-arrestin was that β-arrestin acts as an adapter 
protein between SRC family tyrosine kinases and a GPCR, which 
in turn leads to activation of the MAP kinases ERK 1/2 (120). 
Since then, a variety of β-arrestin-mediated signaling effects 
have been described, including scaffolding for AKT, PI3K, and 
phosphodiesterase 4 (PDE4) in the context of specific receptors 
[reviewed in Ref. (116)]. G protein-independent activation of 
ERK 1/2 through the β adrenergic receptor (β2AR) was reported 
in 2006 by Shenoy et al. (121). Treatment of HEK293 cells with 
isoproterenol, which activates β2AR signaling, led to distinct 
ERK1/2 activation outcomes: rapid ERK1/2 activation sensitive 
to pertussis toxin treatment and therefore Gαi protein-dependent, 
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as well as a slower, more sustained ERK1/2 activation which was 
insensitive to pertussis toxin and thus Gαi protein-independent, 
and which could be abrogated by siRNAs against β-arrestins (121). 
These findings show that the involvement of β-arrestin-mediated 
signaling in the context of GPCRs should not be underestimated. 
When it comes to the function of β-arrestin in regard to CXCL12, 
it clearly emerges that this aspect cannot be investigated with-
out taking the interaction of CXCR4 and ACKR3 into account 
(122–124), as discussed in more detail below.
Homo-Oligomerization of CXCR4 and CXCL12
An important event in the activation of GPCRs is receptor 
dimerization, a process that is of great interest for drug targeting 
(125). Crystallization of CXCR4 in complex with the antagonists 
IT1t and CVX15 or the viral protein ligand vMIP-II revealed the 
existence of a CXCR4 dimer (11, 24). Also, stable, constitutive 
dimerization and even higher-order oligomerization of CXCR4 in 
the absence of a ligand could be shown in fluorescence resonance 
energy transfer (FRET) experiments (126, 127), and binding of 
the ligand CXCL12 was reported to even further increase CXCR4 
oligomerization in FRET experiments (128).
Not only CXCR4, but also CXCL12 can form homodimers, 
and crystallization studies of CXCR4 left open the possibilities of 
CXCL12 interacting as monomer as well as dimer with a CXCR4 
dimer (24). Of note, the oligomerization state of CXCL12 has been 
reported to influence signaling, however with conflicting data 
presented. Ray et al. report on a bias for monomeric CXCL12 to 
initiate G protein-coupled signaling and for dimeric CXCL12 to 
rather promote recruitment of β-arrestin-2 to CXCR4, as shown 
in  vitro in breast cancer cells (129). By contrast, Drury et  al. 
showed in colon carcinoma cells that dimeric CXCL12 has merely 
any effect on β-arrestin, whereas monomeric CXCL12 recruited 
β-arrestin. In this study, both CXCL12 forms however mobilized 
intracellular calcium and inhibited adenylyl cyclase signaling, 
showing activation of Gαi signaling (130). These findings show 
that a clear-cut distinction of the dimerization state of CXCL12 
and its relation to specific downstream signaling pathways can-
not (yet) be made. Furthermore, to which extent dimerization of 
CXCL12 is favored over the monomeric form in vivo still remains 
open and is believed to be highly tissue-dependent (129).
interaction of CXCR4 and CXCL12 with Other 
Signaling Mediators
Apart from homodimerization (24, 126, 127), CXCR4 forms a 
functional MIF receptor complex with CD74 (131) and can form 
heterodimers with the chemokine receptor ACKR3 (previously 
CXCR7), modulating CXCL12/CXCR4 signaling as will be dis-
cussed in detail below. Furthermore, oligomerization of CXCR4 
with CCR5 and CCR2, chemokine receptors important for HIV 
infection, has been shown by FRET and co-immunoprecipitation 
experiments (132–137).
Also, it could be shown that CXCR4 forms a heterodimer 
with the T-cell receptor (TCR) upon stimulation of T-cells with 
CXCL12, leading to several cellular outcomes such as ERK acti-
vation, increased Ca2+ levels, gene transcription, and cytokine 
production (138). For example, a particular factor regulated by 
CXCL12 signaling in a TCR-dependent way is RasGRP1, a Ras 
guanine-nucleotide exchange factor, which activates ERK and has 
important functions in autoimmunity and immunodeficiency 
(139). Interestingly, the heterodimerization of TCR and CXCR4 
was found to be crucial for CXCR4 endocytosis in T-cells (140).
Furthermore, in an intriguing study conducted by Wagner 
et al., it was shown that in a mouse model of hindlimb ischemia, 
the administration of a TLR2 blocking antibody had similar pro-
angiogenic effects compared with administration of CXCL12 and 
induced the activation of both ERK1/2 and AKT, the canonical 
signal transduction pathways of CXCR4. Immunoprecipitation 
experiments revealed an interaction of TLR2 and CXCR4 in 
endothelial cells and it was proposed that the effects of the TLR2 
blocking antibody were mediated through CXCR4. Indeed, upon 
CXCR4 knockdown or G protein inhibition, the observed pro-
angiogenic effects of the TLR2 blocking antibody were abolished, 
supporting a role for a functional interaction of CXCR4 with TLR2 
in mediating pro-angiogenic effects of TLR2 blocking (141).
Furthermore, recent research implicates a functional interac-
tion of a CXCR4/ACKR3 dimer with the androgen receptor, 
regulating CXCL12-dependent cellular motility in a prostate 
tumor cell line (142). Also, heteromerization of CXCR4 with 
α1A/B-adrenergic GPCR has been reported recently in HeLa 
cells and human vascular smooth muscle cells (143). In addition, 
interactions of CXCR4 with CD4, lipopolysaccharide receptor, 
Epstein–Barr virus-encoded GPCR BILF1, kappa-type opioid 
receptor, and delta-type opioid receptor have been described 
[reviewed in Ref. (144)].
Finally, not only CXCR4 but also CXCL12 has been shown 
to interact with other signaling mediators affecting CXCL12/
CXCR4 signaling: high mobility group box 1 (HMGB1), a 
damage-associated molecular pattern released from damaged 
cells, was revealed to form a heterocomplex with CXCL12, shift-
ing the efficiency of CXCR4 activation to lower concentrations 
and mediating inflammatory cell recruitment in vivo (145).
Together, these findings show that the CXCL12/CXCR4 axis is 
not monogamous, but is connected to a variety of other signaling 
receptors.
Biological Processes and Signaling 
Triggered by the MiF/CXCR4 Axis
Migration inhibitory factor is involved in the progression of diverse 
acute and chronic inflammatory diseases including septic shock, 
atherosclerosis, septic lupus erythematosus, bladder pain, and 
allergic diseases such as eosinophilic esophagitis (19, 146–149). 
On the other hand, MIF also exhibits protective functions, e.g., in 
liver fibrosis and myocardial ischemia-reperfusion injury, associ-
ated with the activation of the protective kinases AMPK and PKCε 
(150–153). Recently, a novel protective role of MIF was revealed 
in the developing cerebral cortex upon tissue damage, with MIF 
upregulated upon cell death and stimulating the proliferation of 
microglia in the developing cerebral cortex (154).
CD74, the surface-expressed form of MHC class-II-associated 
invariant chain, has been identified as a MIF receptor. In a signal-
ing complex with CD44, MIF/CD74 interaction leads to ERK1/2 
FiGURe 3 | The signaling network induced by the non-canonical 
CXCR4 ligands MiF, extracellular ubiquitin, and gp120. (A) MIF induces 
signal transduction by binding to the CXCR4, which can form a receptor 
complex with CD74 under certain conditions, or by binding to the atypical 
chemokine receptor 3 (ACKR3) (previously called CXCR7). MIF binding to 
CXCR4 triggers cytosolic Ca2+ influx, integrin activation, and ZAP-70 activation 
via Gαi, resulting in cell adhesion, migration, proliferation, and GRK2 
expression. By binding to the CXCR4/CD74 signaling complex, MIF activates 
ERK1/2 and AKT signaling promoting cell survival and proliferation. 
Additionally, the MIF–CXCR4/CD74 interaction promotes JNK 
phosphorylation, which results in enhanced CXCL8 expression. By binding to 
ACKR3 MIF induces platelet survival via the activation of PI3K and AKT. (B) By 
binding to CXCR4, ubiquitin induces the migration of cancer as well as THP1 
cells through the activation of Gαi-dependent PLC-induced Ca2+ influx, MAPK, 
and AKT phosphorylation. The HIV glycoprotein gp120 uses CXCR4 as 
co-receptor for fusion of viral and host cell membrane, which results in HIV 
infection. In addition, gp120 can induce cell death via CXCR4 by activating 
caspases, p53-dependent cytochrome C release, and PI3K/AKT-dependent 
Fas ligand expression. AKT, protein kinase B; Ca2+, calcium ions; Cyt. C, 
cytochrome C; ERK1/2, extracellular signal-regulated kinases 1/2; Gαi, 
Gi-protein subunit α; gp120, glycoprotein 120; GRK2, G protein-coupled 
receptor kinase 2; JAK, janus kinase; MAPK, mitogen-activated protein 
kinase; MEK, mitogen-activated protein kinase kinase; MIF, macrophage 
migration inhibitory factor; PI3K, phosphatidylinositide 3-kinase; PLC, 
phospholipase C; THP1, monocytic cell line; ZAP-70, zeta-chain-associated 
protein kinase 70.
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and AKT phosphorylation promoting cell survival and prolifera-
tion (155–157) (Figure 3A). The chemotactic properties of MIF 
are mediated via binding to the chemokine receptors CXCR2 
and CXCR4 (4), in part by interaction with CD74. Interaction 
of MIF with CXCR2 has been shown to mediate the recruit-
ment and arrest of monocytes and neutrophils (4, 158), with 
MIF–CXCR2-induced signaling discussed in detail previously 
(19). Via CXCR4, MIF has been shown to recruit many cell types, 
including T-cells, B-cells, eosinophils, endothelial progenitor 
cells, mesenchymal stromal cells, as well as cancer cells (4, 148, 
159–162). Furthermore, MIF–CXCR4 interaction increases in 
experimental bladder inflammation (163), with PAR4-induced 
abdominal hypersensitivity shown to occur through MIF and 
at least partially also through CXCR4 on the urothelium (149). 
However, the underlying signaling events of MIF–CXCR4 asso-
ciation are only partially enlightened.
In T- and B-cells, MIF-induced cell migration is Giα-dependent 
and MIF induces cytosolic Ca2+-influx (4, 161). Furthermore, MIF 
triggers the rapid activation of integrins, as shown in T-cells (4), 
and which induces cell arrest by binding to integrin ligands pre-
sented by, e.g., activated endothelium. In B-cells, both MIF- and 
CXCL12-induced migration are dependent on the participation 
of the tyrosine kinase ZAP-70 (161). ZAP-70 was originally noted 
for its involvement in the initiation of the antigen-dependent 
T-cell response by phosphorylating the scaffold proteins LAT 
and SLP-76 (164). During T-cell migration triggered by CXCL12, 
ZAP-70 regulates directionality by interacting with talin, which 
acts as an integrin scaffold for F-actin (165). Whether ZAP-70 
exerts these same functions in MIF-induced signaling remains 
to be unraveled.
In colon cancer cells, the MIF/CXCR4 axis induces an aggres-
sive phenotype by inducing proliferation, adhesion, migration, 
and invasion of these cells, which is related to metastasis (160, 
166). Similarly, the MIF/CXCR4 axis was recently shown to be the 
main axis mediating the recruitment of mesenchymal stromal cells 
to tumors and underlying their invasion capacity, both in vitro 
as well as in a pulmonary metastasis model, and this was linked 
with signaling through the MAP kinases MEK1/MEK2, upstream 
of ERK1/2 (162). On the other hand, CXCR4-expressing human 
rhapdomyosarcoma cells do not only show phosphorylation of 
ERK1/2 and AKT, but also enhanced cell adhesion after stimula-
tion with MIF, the latter preventing their release into the circula-
tion and thereby inhibits metastasis (7). Therefore, the role of MIF 
in metastasis seems to be ambivalent maybe dependent on tumor 
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type. Interestingly, MIF, which is secreted in response to hypoxia 
by different tumor cells, was reported to induce CD11b+GR1+ 
myeloid cell migration via CD74/CXCR4 and CD74/CXCR2 
complexes, as well as through p38 and PI3K activation (167). 
Because CD11b+GR1+ myeloid cells have gained much attention 
for their role in tumor immunity suppression as well as for their 
ability to promote angiogenesis (168, 169), MIF could support 
tumor growth by recruiting CD11b+GR1+ myeloid cells.
In addition, tumor-originated MIF leads to enhanced accumula-
tion of interleukin-17-producing subsets of tumor-infiltrating lym-
phocytes by binding to CXCR4, which can affect patient prognosis 
(170). The clinical relevance of these interleukin-17-producing 
lymphocyte subsets for cancer seems to be cancer type-dependent. 
While these subsets are beneficial in ovarian cancer, the number 
of interleukin-17-producing subsets negatively predicts the 
outcome of patients with hepatocellular carcinoma (171, 172).
In 2009, Schwartz et al. could show that CXCR4 and CD74 form 
a functional MIF receptor complex, which induces MIF-dependent 
AKT phosphorylation that can be blocked by anti-CXCR4 as well 
as by anti-CD74 antibodies (131) (Figure 3A). After binding to 
this complex, MIF is internalized by clathrin/dynamin-dependent 
endocytosis leading to endosomal AKT signaling (173). This 
CXCR4/CD74-complex also mediates MIF-dependent JNK 
activation via the PI3 and SRC kinases leading to c-Jun and AP-1 
activation to upregulate gene expression of CXCL8 in T-cells (174).
Despite its chemotactic activity, MIF was originally described 
as a substance which inhibits the random movement as well as 
directed migration of macrophages, hence its name “macrophage 
migration inhibiting factor” (175, 176). Later on, this was explained 
by a desensitization effect of MIF toward migration induced by 
other chemokines, as also shown, e.g., MCP1/CCL2- and CXCL8-
induced migration (4, 177). Recently, it was suggested that MIF 
inhibits migration of human monocytic U937 cells through 
CXCR4 in the absence of CD74 via a perturbation of RHO 
GTPase signaling. MIF/CXCR4 interaction was shown to induce 
G protein-coupled activation of RHO-A followed by subsequent 
inactivation. In addition, RAC1 was transiently inactivated while 
Cdc42 showed cyclic activation and inactivation. Together, these 
results were suggested to contribute to MIF-induced migration 
inhibition in U937 cells. Furthermore, they indicate that CXCR4 
can mediate MIF signaling in the absence of CD74, in addition 
to its function as MIF co-receptor in complex with CD74 (178).
Finally, increased levels of MIF, as observed in plasma of 
diabetic patients, also enhance the expression of GRK2 in car-
diomyoblasts, an effect mediated through CXCR4 (179). As an 
upregulation of GRK2 in cardiomyocytes precedes the develop-
ment of heart failure (180), this finding might suggest that MIF 
could promote heart failure by amplifying GRK2 expression.
CXCR4 Signaling Triggered by the  
Non-Canonical Ligands eUb and gp120
extracellular Ubiquitin (eUb)/CXCR4 Signaling
Opposite to the well-characterized functions of ubiquitin as 
intracellular signaling molecule, as discussed earlier, only little 
attention has been paid to its extracellular actions. eUb can be 
found in human serum in concentrations varying in response to 
different diseases. The cellular source and the underlying release 
mechanism remain unclear (181, 182), but active secretion of 
ubiquitin was assumed after increased ubiquitin concentrations 
were measured in the supernatant of Ba/F3 B-cells and 293T 
human embryonic kidney cells after transfection with an ubiqui-
tin expression vector (183). Furthermore, it has been shown that 
eUb can be taken up by cells (184), and induces Ca2+ flux after 
binding to THP1 monocytes. Ubiquitin-induced Ca2+ flux could 
be inhibited by the use of the G protein inhibitor pertussis toxin, 
indicating that ubiquitin signals via a GPCR. By gene silencing and 
the use of the CXCR4 antagonist AMD3100 Saini et al. showed 
that eUb signals via CXCR4 and leads to Ca2+ flux and reduced 
cAMP levels (70). Ubiquitin-induced Ca2+ flux can also be attenu-
ated by the PLC inhibitor U73122, indicating that PLC plays a role 
in ubiquitin-induced signaling events (185) (Figure 3B).
Extracellular ubiquitin has chemotactic properties inducing 
the migration of different cancer cell types as well as THP1 cells 
via CXCR4, PLC, AKT, and the MEK/ERK pathway (186–188). 
The effects of ubiquitin and the canonical CXCR4 ligand CXCL12 
are partially synergistic: co-stimulation with suboptimal ligand 
concentrations leads to enhanced Ca2+ flux, without synergistic 
effects on cAMP levels, AKT and ERK1/2 phosphorylation 
or chemotactic responses (188). In 2011, ubiquitin has been 
characterized as a substrate for the ubiquitously expressed cell 
surface protein “insulin degrading enzyme” (IDE), cleaving the 
C-terminal di-Gly aa from ubiquitin (189). This modification 
modulates CXCR4-mediated ubiquitin signaling. Reduced IDE 
expression enhances the ubiquitin-induced reduction in cAMP 
levels and reinforces the chemotactic activity of ubiquitin (186). 
Modulation of ubiquitin by IDE could thereby contribute to the 
fine-tuning of CXCR4-mediated cell functions.
Gp120/CXCR4 Signaling
Binding of gp120 on the surface of the HI-virus to CD4 and the 
HIV co-receptors CCR5 or CXCR4 leads to the fusion of the 
viral and the host cell membrane (79). Also, binding of gp120 to 
CXCR4 is involved in HIV-mediated apoptosis of infected and 
uninfected lymphocytes (190), neurons (191), cardiomyocytes 
(192), hepatocytes (193), and different cancer cells (194, 195). 
The underlying signaling events are controversially discussed 
(Figure 3B). CXCR4 signaling is typically mediated via the Gαi 
protein. But in case of gp120/CXCR4-mediated apoptosis, the 
signaling pathway seems to be Gαi protein-independent, at least 
in T-cells (196, 197), whereas gp120/CXCR4-induced apoptosis 
of breast cancer cells (194) and hepatocytes (193) depends on Gαi 
protein involvement. Also, the participation of caspases seems to 
be cell type-dependent: caspases 8 and 9 play an essential role 
in gp120/CXCR4-induced apoptosis of cardiomyocytes (192); 
gp120/CXCR4-induced apoptosis of hepatocytes is caspase-inde-
pendent (193); but T-cells seem to display a caspase-independent 
pathway as well as a pathway involving caspases 3 and 9 (197, 
198). By the use of CD4 inhibitors or CD4 mutants, different 
studies reported that gp120/CXCR4-induced apoptosis is CD4-
independent. By contrast, CD45 was observed to be important for 
gp120/CXCR4-mediated T-cell apoptosis, and through interac-
tion with CXCR4, CD45 is involved in Fas ligand activation via 
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the PI3K/AKT pathway (199). Gp120 expression on the surface 
of infected cells can also cause apoptosis by binding to a CD4/
CXCR4-expressing cell. The resulting “fused cell,” also called 
syncytium, undergoes apoptosis mediated by mitochondrial 
membrane permeabilization and cytochrome c release involving 
p53 activation (200, 201).
To gain more insight into the molecular mechanisms leading 
to gp120/CXCR4-mediated apoptosis of lymphocytes, Molina 
et al. performed a proteomic analysis of immune cells after cocul-
ture with cells expressing gp120. This approach showed that most 
proteins involved in gp120/CXCR4-mediated apoptosis can be 
linked to degradation processes, redox homeostasis, metabolism, 
or cytoskeleton dynamics (202). Not only apoptosis but also 
autophagy of CD4 T-cells can be induced by gp120 binding to 
CXCR4, but the underlying signaling events remain unclear 
(203). Because gp120/CXCR4-induced lymphocyte death leads 
to pathological immunodeficiency, a lot of research is still ongo-
ing to identify a CXCR4 antagonist that would selectively prevent 
the gp120/CXCR4 interaction and thereby HIV-triggered disease 
progression (204).
ACKR3 influences Signaling through 
CXCR4
Atypical chemokine receptor 3 (ACKR3) (originally named RDC-1 
or CXCR7) was first described in 1989 as a putative GPCR cloned 
from thyroid complementary DNA (205). Further evidence for 
RDC-1 belonging to the seven-transmembrane-spanning recep-
tor family was obtained by sequence analysis (206). The notion 
that RDC-1 might be part of the CXC family of chemokine recep-
tors was brought up by Heesen et al., who reported in 1998 a 55% 
nucleic acid similarity between mouse RDC-1 and rabbit CXCR2 
(207). In 2005, Balabanian et al. identified the orphan receptor 
RDC-1 as another receptor for CXCL12 and hence suggested to 
rename it to CXCR7 according to the chemokine nomenclature 
(6). In 2014, the name was changed into ACKR3 (12). Of note, 
ACKR3 was reported to have a ~10-fold higher affinity for CXCL12 
compared with CXCR4 (6, 36, 208). This finding has considerably 
changed the view of CXCL12/CXCR4 signaling, as CXCR4 was 
until then believed to be the only receptor for CXCL12, and since, 
ACKR3 has been under intensive investigation.
ACKR3 is expressed in a variety of tissues, including, for 
example, embryonic neuronal and heart tissue, hematopoietic 
cells, and activated endothelium (209). Its expression has also 
been linked to a variety of cancers, including, for example, breast 
and lung tumors (210), brain metastases (211), and renal cell 
carcinoma (212). Apart from cancer research, ACKR3 has been 
implicated in other diseases, for example in acute coronary syn-
drome, in which platelets from patients showed enhanced surface 
expression of ACKR3 but not CXCR4 (213).
CXCL12 as a Ligand for ACKR3 and interrelation 
with CXCL12/CXCR4 Signaling
With ACKR3 as a high-affinity receptor for CXCL12 (6, 36, 208), 
ACKR3 functions as a scavenger receptor for CXCL12, thereby 
downtuning classical CXCL12/CXCR4 signaling. On the other 
hand, ACKR3 is also able to induce CXCL12 signaling indepen-
dently from CXCR4 (6, 214–216), as will be discussed in more 
detail below. It is currently thought that ACKR3 does not per se 
induce G protein signaling upon binding of CXCL12, based on 
which the previous name CXCR7 was recently renamed into 
ACKR3 based on its classification in the group of ACKRs that 
do not signal through G proteins (12), although this has been 
challenged by others (217).
ACKR3 continuously cycles between the plasma membrane 
and intracellular compartments without or with ligand binding, 
and in contrast to CXCR4, ACKR3 is not degraded after inter-
nalization (209) (Figure 2). ACKR3 internalization is dependent 
on β-arrestin and also involves constitutive ubiquitination for 
correct trafficking of ACKR3 (218).
Co-expression of CXCR4 with ACKR3 resulted in heter-
odimerization independent of ligand binding (219). This was 
associated with a constitutive recruitment of β-arrestin-2 to the 
CXCR4/ACKR3 complex, with simultaneous down-regulation of 
Gαi-mediated signaling as shown by a cAMP reporter gene assay 
as read-out of Gαi signaling (123) (Box 4; Figure 2). Based on 
these results, Decaillot et al. postulated that the CXCR4/ACKR3 
heterodimer down-tunes classical CXCL12/CXCR4-triggered G 
protein-coupled signaling by preferentially triggering the recruit-
ment of β-arrestin and hence inducing β-arrestin-mediated sign-
aling pathways, including activation of the MAP kinases ERK1/2, 
p38 and SAPK. The activation of these pathways is enhanced by 
binding of CXCL12 to the receptor complex, which leads to an 
increased recruitment of β-arrestin compared to the interaction 
of CXCL12 with CXCR4 alone (123). Of note, CXCR4/ACKR3 
heterodimers form as efficiently as CXCR4 homodimers, indicat-
ing that these mechanisms are of equal importance (219).
Furthermore, recent reports showed additional negative 
regulatory functions of ACKR3 toward classical CXCL12/CXCR4 
signaling: an agonist of ACKR3 promoted the dimerization of 
ACKR3 with CXCR4, which in turn led to internalization and 
degradation of CXCR4 and inhibition of CXCL12-induced 
tube formation (124). Also, ACKR3 binding to CXCL12 but 
also to its other ligand CXCL11 (as discussed below) enhances 
internalization of the chemokine ligand/receptor complex and 
results in lysosomal degradation of the chemokine ligand (209, 
220), which again negatively affects CXCL12/CXCR4 signaling. 
Together, these findings have led to the current idea that the 
CXCR4/ACKR3 complex results in decreased classical signaling 
of CXCL12/CXCR4 through G protein-coupled pathways and 
initiation of β-arrestin signaling through ACKR3.
Of note, ACKR3 preferentially sequesters the monomeric form 
of CXCL12, whereas dimeric CXCL12 showed significantly lower 
binding to ACKR3 in vitro and in a breast cancer xenograft model 
(129). However, how the oligomerization state of CXCL12 influ-
ences downstream signaling remains controversial, as discussed 
earlier. Taking into account the findings by Drury et  al. who 
showed in colon carcinoma cells that monomeric but not dimeric 
CXCL12 preferentially recruited β-arrestin to CXCR4 (130), one 
could hypothesize that enhanced β-arrestin signaling through 
ACKR3 is due to preferential binding of monomeric CXCL12. 
However Ray et  al. reported that monomeric CXCL12 actu-
ally promotes Gαi signaling through CXCR4, whereas dimeric 
August 2015 | Volume 6 | Article 42914
Pawig et al. The CXCR4 receptor/ligand family: molecular perspectives
Frontiers in Immunology | www.frontiersin.org
CXCL12 rather recruited β-arrestin (129). This shows that these 
mechanisms still need to be further investigated and could possibly 
be cell type-dependent and influenced by the build-up of different 
receptor complexes, as, for example, homomeric or heteromeric 
interactions involving CXCR4, ACKR3, and even CD74.
Furthermore, different reports come to the conclusion that 
CXCL12 can signal through ACKR3 independently of CXCR4, 
further diversifying the potential mechanisms of the CXCL12 
signaling network (Figure 2). The migration of neural progenitor 
cells was shown to be regulated by CXCL12, both through the 
well-established mechanism of CXCR4 but also independently of 
CXCR4 via ACKR3 (216). Similarly, CXCL12 can induce T-cell 
migration through ACKR3 independent of CXCR4 (6, 215), 
and in cortical interneurons MAPK activation can be induced 
by CXCL12/ACKR3 independent of CXCR4 (214). However, 
the idea that ACKR3 is merely a scavenger receptor modulating 
CXCR4 function and an ACKR not coupled to classical G protein 
signaling was in turn challenged by Ödemis et al., who showed 
that ACKR3-mediated effects on ERK and AKT activation in 
rodent astrocytes and human glioma cells were pertussis toxin-
sensitive, and hence mediated by G protein activation (217).
In conclusion, the previous view of classical CXCL12/CXCR4 
signaling needs to take into account active signaling moderation 
by ACKR3. Whether CXCL12 signaling is mediated through 
CXCR4, ACKR3, or both receptors in conjunction seems to 
be cell type-dependent (221). Interestingly, a recent report 
described CXCL12 to stimulate CXCR4 internalization on plate-
lets, which in turn led to increased ACKR3 surface expression. 
This CXCR4-dependent increased ACKR3 surface exposure had 
anti-apoptotic effects on platelets (222). These findings reveal a 
highly interesting, novel pro-survival mechanism of CXCL12, 
and also demonstrate that CXCR4 and ACKR3 can work in 
close conjunction to trigger specific biological effects. However, 
signaling through CXCR4 vs. ACKR3 can also have opposite bio-
logical effects. For example, it was recently shown that ACKR3 is 
upregulated in liver sinusoidal endothelial cells after acute liver 
injury and in cooperation with CXCR4 induces liver regeneration 
through the production of pro-regenerative angiocrine factors. 
By contrast, chronic liver injury increased CXCR4 expression, 
overwhelming ACKR3 signaling and promoting a pro-fibrotic 
response instead (223).
CXCL11 as a Ligand for ACKR3
In 2006, ACKR3 (at that time still called CXCR7) was also 
identified as a receptor for the chemokine CXCL11, which was 
previously believed to exclusively bind to CXCR3 (208, 224). This 
chemokine was discovered in 1998 by Cole et  al. by sequence 
analysis of cDNAs derived from cytokine-activated primary 
human astrocytes (224), and based on experiments named as 
interferon-inducible T-cell alpha chemoattractant (I-TAC). Later 
on, this name was replaced by CXCL11, according to the common 
chemokine nomenclature (225, 226). Interactions of CXCL11 with 
CXCR3 have been intensively investigated, and have, for example, 
been associated with several pro- as well as anti-tumorigenic 
effects (227). By contrast, the CXCL11/ACKR3 relationship is 
less well studied. Yet, it clearly emerges that CXCL12, CXCL11, 
and their common receptor ACKR3 form an interactive network. 
For example, local administration of CXCL11 in a mouse model 
of colorectal cancer enhanced tumor growth. Without exogenous 
CXCL11 stimulation, blocking endogenous CXCL11 or CXCL12 
alone did not influence tumor growth and angiogenesis, whereas 
the combined inhibition almost completely abrogated tumor 
angiogenesis, providing evidence for the proposed close relation-
ship of these chemokines (228).
Potential Alternative Ligands for ACKR3:  
MiF and gp120
Apart from the binding of CXCL12 and CXCL11, ACKR3 has 
also been implied as a receptor for MIF (Figure 3A). For example, 
an anti-ACKR3 antibody inhibited the adhesion of rhabdo-
myosarcoma cells in response to MIF in an in  vitro assay (7). 
Furthermore, a recent report indicated MIF to interact with both 
CXCR4 and ACKR3 on the platelet surface, although biochemical 
receptor binding evidence is currently still elusive. Although MIF 
could also induce CXCR4 internalization similar to CXCL12, MIF 
was not able to induce downstream ERK phosphorylation upon 
CXCR4 binding and also failed to induce subsequent upregula-
tion of ACKR3 externalization, likely due to lack of CD74, which 
is not expressed in platelets. However, MIF-induced platelet 
survival through ACKR3 but not CXCR4, as well as activation of 
the PI3K–AKT pathway (229). The injection of MIF in a mouse 
model led to decreased thrombus formation after arterial injury, 
which could be abrogated by a ACKR3-blocking antibody. In vitro, 
reduced thrombus formation by MIF was mediated through both 
CXCR4 and ACKR3 (229).
Finally, the similarity of ACKR3 to CXCR4 in ligand binding is 
also apparent by the ability of both receptors to act as co-receptors 
for several strains of HIV in combination with CD4 (230). While 
for CXCR4, binding of the HIV envelope glycoprotein gp120 is a 
well-established mechanism for viral entry (231), interaction of 
HIV envelope proteins to ACKR3 has not yet been demonstrated 
by biochemical receptor binding assays.
involvement of (Defective) CXCR4 
Signaling in Pathological Settings
Since CXCR4 signaling is induced by different ligands and affects 
important biological processes, it is not surprising that CXCR4 
is also involved in a plethora of pathological events, such as HIV 
infection (15, 179), WHIM syndrome (232), as well as diverse 
cancer types (96).
As already introduced before, CXCR4 is important for HIV 
entry into T-cells of infected patients, and this conclusion 
is underlined by the fact that administration of the CXCR4 
antagonist AMD3100/Plerixafor can stop virus replication (9). 
Therefore, CXCR4 antagonists are still under thorough investiga-
tion for their potential therapeutic value in HIV infection (233).
The warts, hypogammaglobulinemia, infection, and 
myelokathexis (WHIM) syndrome was first described in 1990 
by Wetzler et  al. (234). WHIM syndrome is characterized by 
severe neutropenia despite having abundant mature myeloid 
cells in the bone marrow, which is termed myelokathexis (232). 
Gain-of-function mutations in the CXCR4 gene were identified 
as the underlying cause of this autosomal-dominant syndrome in 
TABLe 1 | Ongoing clinical trials with CXCR4 antagonists as listed in the 
database at clinicaltrials.gov (search term “CXCR4”).
Drug Clinical  
trial phase
Being tested in Sponsor
BMS-936564 Phase 1 Multiple myeloma Bristol–Myers Squibb
BKT140 Phase 1/
phase 2




Chronic myeloid leukemia Sheba Medical Center




BMS-936564 Phase 1 Acute myelogenous 
leukemia; diffuse large 








HIV infections National Institute of 
Allergy and Infectious 
Diseases (NIAID); AIDS 
Clinical Trials Group
MSX-122 Phase 1 Solid tumors Metastatix, Inc.
POL6326 Phase 1 Mobilization of 
hematopoietic stem cells 
in healthy volunteers
Polyphor Ltd.
AMD070 Phase 1 HIV infections National Institute of 
Allergy and Infectious 
Diseases (NIAID); AIDS 
Clinical Trials Group
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2003 (232, 235), corresponding to the fact that CXCR4 mediates 
neutrophil retention in the bone marrow (93). A highly interest-
ing finding on WHIM was published this year; McDermott et al. 
report a case in which a patient with WHIM was spontaneously 
cured by chromothripsis, an intensive deletion and rearrangement 
process in chromosomes. Here, the defective CXCR4 gene was 
randomly deleted in a hematopoietic stem cell that repopulated 
the myeloid but not the lymphoid lineage, leading to complete 
remission of the patient (235).
Furthermore, CXCR4 is the chemokine receptor most widely 
expressed in malignant tumors (236). It plays a role in a variety 
of cancer types, and has been linked with cancer cell proliferation 
and metastasis to bones and lymph nodes through both CXCL12 
and MIF, as described above (96, 160, 166). For example, activa-
tion of CXCR4 induces leukemia cell trafficking and homing 
to the bone marrow (237) and is critical for the growth of both 
malignant neuronal and glial tumors (238).
In contrast to pathological effects of CXCR4 signaling, CXCR4 
also exerts important protective functions in the context of disease. 
For example, the CXCL12/CXCR4 axis exerts cardioprotective 
effects after myocardial ischemia by enhancing the incorporation 
of progenitor cells in the infarcted region and promoting survival 
of cardiomyocytes (98, 99, 239). On the other hand, CXCR4 also 
promotes the recruitment of inflammatory cells to the infarcted 
heart (240, 241) and has in this context been linked to an increase 
in infarct area (240). This indicates a double-edged role of CXCR4 
in myocardial ischemia (241), which has also been described for 
MIF (242), as discussed in detail in recent reviews (1, 243), and 
warns for a careful evaluation of effects of CXCR4 antagonists in 
clinical trials.
Development and Clinical Use of CXCR4 
Antagonists
Since CXCR4 signaling is involved in a plethora of pathological 
processes, small-molecule antagonists directed against CXCR4 
are of great interest for medical treatment. A large variety of drug 
candidates and lead compounds targeting CXCR4 have been dis-
covered over the last years, with several classes of chemical com-
pounds being investigated. While peptide-derived compounds 
were the earliest anti-CXCR4 agents under investigation, they 
had poor pharmacokinetic properties. Nevertheless, these com-
pounds were essential for the development of a basic pharmaco-
phore model to further develop more intricate smaller molecules 
antagonizing CXCR4. These include cyclic pentapeptide-based 
antagonists, indole-based antagonists, tetrahydroquinolines-
based antagonists, para-xylyl-enediamine-based compounds, 
guanidine-based antagonists, quinoline derivatives, and various 
other compounds, as reviewed in detail recently (2). The first 
and so far only CXCR4 antagonist that was approved by the 
Food and Drug Administration (FDA) is AMD3100, a bicyclam 
compound marketed under the brand name Plerixafor (Genzyme 
Corporation). It is being used in combination with G-CSF for the 
mobilization of HSPCs for autologous transplantation in patients 
with non-Hodgkin’s lymphoma (244). The use of HSPCs, derived 
by treatment with G-CSF and AMD3100, has essentially replaced 
bone marrow as a source of stem cells for both autologous and 
allogeneic transplantation, providing greater safety for the patient 
(245). In addition to the FDA-approved Plerixafor, other CXCR4 
antagonists are being evaluated in ongoing clinical trials. To date, 
nine other clinical trials with CXCR4 antagonists are listed in the 
database at clinicaltrials.gov (search term “CXCR4”) (Table 1).
In addition to ongoing clinical trials, several different CXCR4 
antagonists are under investigation in in vitro and in vivo experi-
mental research. For example, TG-0054 has recently been investi-
gated for its therapeutic potential in an animal model of myocardial 
infarction. It could be shown that the administration of TG-0054 
after induction of myocardial infarction leads to a mobilization of 
mesenchymal stem cells, preventing left ventricular dysfunction 
and causing a decrease in inflammatory cytokine levels (246). A 
phase II clinical trial to assess the pharmacokinetics and safety 
of TG-0054 for the mobilization of stem cells in patients with 
multiple myeloma, non-Hodgkin lymphoma, or Hodgkin disease 
has been completed by the end of 2014; however, the results have 
not been published to date (clinical trials NCT01458288).
Since AMD3100 is currently the only FDA-approved CXCR4 
antagonist, it is being used in multiple clinical trials (search term 
“AMD3100” at clinicaltrials.gov reveals 112 hits). Additionally, 
researchers are constantly aiming to improve AMD3100, for 
example, efforts to increase its anti-HIV properties by functional-
izing the phenyl moiety are still ongoing (233). Mechanistically, 
AMD3100 prevents the binding of CXCL12 to CXCR4 and 
thus CXCR4 downstream signaling. AMD3465, an analog of 
AMD3100, similarly prevents CXCL12 binding to CXCR4 with 
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an even 10-fold higher effectiveness (247), however did not 
yet receive FDA approval. Of note, AMD3100 was previously 
reported to be able to enhance CXCL12 binding to ACKR3 and to 
induce basal as well as CXCL12-induced β-arrestin recruitment 
to ACKR3 above concentrations of 10 μM, warranting AMD3100 
not only to interfere with CXCR4 signaling but also to induce 
ACKR3 signaling at high concentrations or modulate CXCL12 
scavenging through ACKR3 (248).
Concluding Remarks
In the last decade, many new insights in the CXCR4 signaling 
cascade have been revealed, both in terms of the ligands to which 
CXCR4 binds, the different signaling pathways that are initiated 
downstream, the formation of heteromeric receptor complexes 
involving CXCR4, as well as the interaction of other receptor 
complexes with the CXCR4 cascade. This will considerably help 
to understand the functions of CXCR4 and its ligands both in 
physiological settings as well as in disease. However, there is 
still a lot of haziness that remains to be clarified. For example, 
the specific residues of CXCR4 involved in the site 1 and site 
2 interaction with CXCL12 vs. MIF are still unknown, as is its 
affinity to CXCL12 compared to MIF binding in physiological 
settings, and thus the potential competition between CXCL12 
and MIF for CXCR4 binding. Furthermore, both CXCL12 and 
MIF can interact with ACKR3, and, despite the initial view 
that ACKR3 merely serves as a chemokine decoy receptor, first 
reports have now indicated that both MIF- and CXCL12-induced 
ACKR3 signaling regulate important biological processes, and 
it can be expected that additional functions of these signaling 
pathways in both physiological as well as pathological conditions 
will be revealed. Also, the roles of CXCR4, CXCL12, and MIF 
in certain physiological or pathophysiological settings may be 
very complex depending on the cell type, microenvironment, 
and perhaps potentially inter-individual settings. For example, 
CXCR4, CXCL12, as well as MIF have been associated with a 
pro- as well as anti-inflammatory role after myocardial infarc-
tion (98, 99, 239–242), and also in the context of injury-induced 
restenosis, CXCR4 has been associated with detrimental as well as 
protective effects (249, 250), as discussed in more detail recently 
by Döring et al. (1). Based on the fact that CXCR4 can interact 
with ACKR3 and CD74, but also other receptors as TLR2, it could 
be speculated that these double-edged functions may result from 
the involvement of differential receptor complexes that initiate 
different intracellular signaling pathways. Revealing differential 
interaction sites for CXCR4 with CXCL12 vs. MIF, and differential 
signaling pathways that mediate pro- vs. inflammatory properties 
could reveal new strategies to target only specific aspects of the 
CXCR4 signaling cascade, while leaving others unaffected to 
prevent unwanted side effects.
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